[144] Agios Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 indicating the intended sale of 1,761 common shares through Morgan Stanley Smith Barney LLC. The shares were acquired via the vesting of restricted stock units on 24 June 2025 and are targeted for sale on the same date. At an aggregate market value of $60,596, the proposed disposition represents roughly 0.003 % of the company’s 57.9 million shares outstanding. No other sales have been reported by the filer during the past three months.

The notice affirms that the seller possesses no undisclosed material adverse information about AGIO at the time of filing, as required under Rule 144. Because the volume and value are immaterial relative to the company’s market capitalization and daily trading volume, the filing is largely routine and unlikely to affect the share price.

Insights

Securities Analyst

TL;DR: Small Form 144 sale (0.003 %)—routine, negligible market impact.

The filing discloses a prospective divestiture of 1,761 AGIO shares, equal to roughly three-thousandths of one percent of shares outstanding. Aggregate value is about $60k, suggesting the transaction is likely part of normal employee equity compensation rather than a strategic insider exit. No pattern of recent sales is noted, and the seller attests to possessing no non-public negative information. From a liquidity standpoint, the volume is trivial relative to AGIO’s average daily trading volume, so price pressure should be minimal. Overall, the filing is informational with no material financial ramifications.

Corporate Governance Expert

TL;DR: Standard RSU-related insider sale; governance risk unchanged.

Rule 144 filings help investors monitor insider activity. Here, the sale stems from RSU vesting, not open-market buying or selling based on discretionary timing. Because only 1,761 shares are involved, this does not signal a change in insider sentiment or governance posture. The certification that the seller lacks undisclosed adverse information mitigates information-asymmetry concerns. Consequently, the event is governance-neutral and does not alter the company’s risk profile.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1761	60596.00	57915199	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/24/2025	Vesting of Restricted Stock Units	Issuer			1761	06/24/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does AGIO's latest Form 144 filing disclose?

It discloses an intended sale of 1,761 common shares of Agios Pharmaceuticals by an insider under Rule 144.

What is the aggregate market value of the AGIO shares to be sold?

The filing lists an aggregate market value of $60,596 for the proposed sale.

When is the approximate sale date for the AGIO shares?

The filing specifies an approximate sale date of 24 June 2025.

How many shares of AGIO are outstanding according to the filing?

There are 57,915,199 shares outstanding.

What percentage of AGIO’s outstanding shares does this sale represent?

About 0.003 % of the company’s outstanding shares.

Who is the broker managing the proposed sale of AGIO shares?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York.